Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Catalent Eyes San Diego, California, for Clinical Supply Hub

09/09/2019
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, will invest $9 million in a new clinical supply facility in San Diego, California.

The new 24,257 square-feet facility, due to open in the summer of 2020, will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials.

Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.

Located less than a mile from the company’s West Coast early-phase oral drug product development center of excellence, the new facility enhances Catalent’s OptiForm Total Supply service, offering customers fully integrated development, clinical supply manufacturing and distribution. This integrated approach helps customers minimize overall project risks and can significantly reduce the time taken to move a program from development into clinic.

“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the U.S. and Canada’s drug development region.”

Catalent’s existing San Diego facility is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being in Somerset, New Jersey and Nottingham, United Kingdom.

Share

Exclusive Research